Eric Bartky
Child & Adolescent Psychiatry · Livingston, NJNPI 1023233426
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,750 of the $50,622 with a category attached, or 70.6%. Supernus Pharmaceuticals, Inc. accounts for 77.8% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $22,127 and has fallen 92.6% since, to $1,639 in 2025. Among child & adolescent psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 626 payments — averaging $80.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$39K
- Ironshore Pharmaceuticals Inc.$5K
- AbbVie$972
- Neos Therapeutics, LP$710
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$688
- Otsuka America Pharmaceutical, Inc.$672
- plus $3K from 26 others
What the payments were for
- Consulting fees$4,0008%
- Speaking & faculty fees$35,75071%
- Travel & lodging$2,1554%
- Food & beverage$8,71017%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 122 | $39,386 |
| Ironshore Pharmaceuticals Inc. | 49 | $5,081 |
| AbbVie | 84 | $972 |
| Neos Therapeutics, LP | 64 | $710 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $688 |
| Otsuka America Pharmaceutical, Inc. | 49 | $672 |
| Lundbeck LLC | 29 | $449 |
| Tris Pharma Inc | 25 | $418 |
| Johnson & Johnson | 27 | $405 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $399 |
| Corium, LLC | 21 | $244 |
| Sunovion Pharmaceuticals Inc. | 12 | $153 |
| Axsome Therapeutics, Inc. | 9 | $139 |
| Jazz Pharmaceuticals Inc. | 9 | $132 |
| Neurocrine Biosciences, Inc. | 5 | $93 |
| Rhodes Pharmaceuticals L.p. | 6 | $80 |
| Validus Pharmaceuticals LLC | 5 | $65 |
| Alkermes, Inc. | 4 | $64 |
| Collegium Pharmaceutical, Inc. | 4 | $63 |
| Arbor Pharmaceuticals, Inc. | 4 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Neuronetics, Inc. | 2 | $42 |
| Shire North American Group Inc | 3 | $39 |
| Alfasigma USA, Inc. | 3 | $37 |
| Tempus AI, Inc | 2 | $32 |
| Avion Pharmaceuticals | 2 | $29 |
| OWP Pharmaceuticals, Inc. | 2 | $28 |
| Vertical Pharmaceuticals, LLC | 2 | $27 |
| Adlon Therapeutics L.p. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| GSK | 1 | $16 |
| Harmony Biosciences LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$32,764
- Jornay PM 20mg capsules (Bottle of 100)$4,157
- JORNAY PM$121
How this compares
$50,622 in reported general payments places this provider in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.
See all child & adolescent psychiatry providers in New Jersey →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EmsamSelegiline | 13 | $27,435 |
| VyvanseLisdexamfetamine Dimesylate | 27 | $11,862 |
| Sertraline Hcl | 40 | $2,219 |
| Paliperidone ErPaliperidone | 13 | $1,356 |
| Bupropion XlBupropion Hcl | 28 | $953 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $484 |
| Clonazepam | 51 | $456 |
| Gabapentin | 20 | $359 |
| Olanzapine | 16 | $274 |
| Bupropion Hcl SrBupropion Hcl | 12 | $228 |
| Mirtazapine | 15 | $223 |
| Fluoxetine Hcl | 11 | $176 |
| Benztropine Mesylate | 13 | $166 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $165 |
| Escitalopram Oxalate | 34 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $399 | $11,86227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.
Other child & adolescent psychiatry in Livingston
- Shaley SehgalLivingston$578
- Ravinder BhallaRidgewood$125K
- Steven DyckmanEast Brunswick$53K
- Bohdan CzartoryskyParsippany$21K
- Akhtar HossainSomerville$19K
- Suzanne LindNew Brunswick$18K
- Aykut OzdenEdgewater$17K
- Valeria KorshunovaHackensack$12K
- Carol DobrzynskiBrick$10K
- Saranga BhallaPrinceton$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.